Cover Image
市場調查報告書

Ranibizumab的中國市場分析

Investigation Report on China Ranibizumab Market, 2012-2019

出版商 China Research and Intelligence 商品編碼 336268
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Ranibizumab的中國市場分析 Investigation Report on China Ranibizumab Market, 2012-2019
出版日期: 2015年07月24日 內容資訊: 英文 20 Pages
簡介

Ranibizumab是老齡化的黃斑變種 (AMD) 的治療藥,中國在2012年由CFDA (國家食品藥品監督管理總局)認證。現在上市的只有是Lucentis (Novartis開發),不過,2013年12月國內廠商自主開發的治療藥也受認證。Ranibizumab市場轉向上市急速擴大,在國內19處醫院的銷售額是2億4500萬人民幣 (2014年),過去3年的市場成長率達到200%。

本報告提供中國的Ranibizumab的市場相關分析、市場整體規模趨勢(過去3年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來市場趨勢預測(今後5年份)等調查評估。

第1章 Ranibizumab的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Ranibizumab市場概況

  • 中國國內的Ranibizumab的專利申請、認證情形
  • 主要製造商
  • 市場規模

第3章 Ranibizumab銷售情形分析 (過去3年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Ranibizumab市場:主要廠商的市場佔有率分析 (過去3年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的Ranibizumab市場:各劑型分析 (過去3年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 Ranibizumab的醫院用標準價格

第7章 中國國內的Ranibizumab的主要製造商 (過去3年份)

第8章 中國的Ranibizumab市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1507276

As macular is the area responsible for high-resolution vision near the center of the retina, macular degeneration, once occurred, will lead to a loss of central vision and distorted vision in the form of metamorphopsia or even irreversible blindness. According to a report published by WHO in 2012, 30 million people suffer from macular degeneration globally, among which about 500,000 end up in blindness per year. In the US, blindness cases caused by macular degeneration outnumbers those caused by glaucoma, cataract and diabetic retinopathy. According to a Chinese investigation in 2012, the incidence of macular degeneration reaches up to 15.5% among old people aged above 50 and 20.2% among those aged above 70. With ageing population, the incidence of macular degeneration will continue to go up.

Developed by Novartis, ranibizumab was approved by CFDA to treat wet age-related macular degeneration (AMD) in 2012. Currently, only Lucentis, a product of Novartis, is available in the Chinese market. However, in Dec. 2013, as the first self-developed drug for the treatment of wet AMD in China, conbercept ophthalmic injection got CFDA's approval.

Ranibizumab develops fast after entering China, sales value in 19 sample hospitals in key cities in 2014 reaching CNY 245 million with a year-on-year growth of 26.29% and CAGR during the last three years reaching 200%. With ageing population, the incidence of macular degeneration goes up gradually. Hence the vast demand for ranibizumab in China. Currently, ranibizumab injections in mainland China all come from Novatis. But as conbercept ophthalmic injection is proved by the clinical studies to improve vision better with a lower administration frequency, it is expected to break the monopoly of Novatis in the wet AMD drug market in the next few years.

Readers can get at least the following information from this report:

  • market size of ranibizumab in China
  • competitive landscape of ranibizumab in Chinese market
  • price of ranibizumab made by different enterprises in China
  • market outlook of ranibizumab in China

The author suggests the following groups of people purchase this report:

  • manufacturers of monoclonal antibody
  • manufacturers of ophthalmic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Ranibizumab

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Ranibizumab in China

  • 2.1. Patent Status and Approval Information of Ranibizumab in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Ranibizumab in China, 2012-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Ranibizumab in China, 2012-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Ranibizumab in China, 2012-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Ranibizumab in Chinese Hospitals in 2014

7. Major Manufacturers of Ranibizumab in Chinese Market, 2012-2014

8. Market Outlook of Ranibizumab in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Ranibizumab in China
  • Chart Registration Information of Ranibizumab in China
  • Chart Sales Status of Ranibizumab in China
  • Chart Sales Value of Ranibizumab in China, 2012-2014
  • Chart Sales Value of Ranibizumab in Some Regions in China, 2012-2014
  • Chart Sales Volume of Ranibizumab in China, 2012-2014
  • Chart Sales Volume of Ranibizumab in Some Regions in China, 2012-2014
  • Chart Price of Ranibizumab Made by Novartis in Some Chinese Cities in 2014
Back to Top